I-Mab (IMAB) Expected to Announce Earnings on Wednesday

I-Mab (NASDAQ:IMAB) is projected to release its Q2 2025 results before the market opens on Wednesday, August 27th. Analysts expect I-Mab to post earnings of ($0.10) per share for the quarter. Interested persons can check the company’s upcoming Q2 2025 earningsummary page for the latest details on the call scheduled for Thursday, August 28, 2025 at 7:00 AM ET.

I-Mab Price Performance

Shares of IMAB opened at $4.21 on Wednesday. The firm has a 50 day simple moving average of $2.68 and a 200-day simple moving average of $1.57. I-Mab has a 1-year low of $0.60 and a 1-year high of $5.90.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on IMAB. Wall Street Zen cut shares of I-Mab from a “buy” rating to a “hold” rating in a research note on Sunday, July 20th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of I-Mab in a research note on Wednesday, July 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $5.00 price objective on shares of I-Mab in a research note on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $6.00.

Institutional Trading of I-Mab

An institutional investor recently raised its position in I-Mab stock. Geode Capital Management LLC boosted its stake in shares of I-Mab Sponsored ADR (NASDAQ:IMAB) by 147.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,562 shares of the company’s stock after purchasing an additional 32,525 shares during the period. Geode Capital Management LLC owned approximately 0.07% of I-Mab worth $132,000 at the end of the most recent reporting period. 38.38% of the stock is owned by hedge funds and other institutional investors.

I-Mab Company Profile

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors.